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Clinical PerspectiveWhat Is New?Data about rivaroxaban following J‐ROCKET AF (Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) criteria compared with warfarin and ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) dosage were limited, and compared with warfarin, rivaroxaban following either dosage criteria was effective and even safer.The J‐ROCKET AF dosage was as effective as the ROCKET AF dosage criteria for the prevention of ischemic stroke/systemic embolism irrespective of renal function.Compared with the ROCKET AF dosage, the risk of major bleeding tended to be lower with J‐ROCKET AF dosage in patients with impaired renal function.What Are the Clinical Implications?J‐ROCKET AF dosage criteria may be reasonable for Asian patients with AF, but should be further tested in prospective and randomized trials.

Introduction {#jah34541-sec-0008}
============

Atrial fibrillation (AF) is the most common cardiac arrhythmia, with a global prevalence of 2% to 3%, which significantly increases the risk for thromboembolic events, congestive heart failure, and mortality.[1](#jah34541-bib-0001){ref-type="ref"}, [2](#jah34541-bib-0002){ref-type="ref"}, [3](#jah34541-bib-0003){ref-type="ref"} Stroke prevention with oral anticoagulants is important for the management of patients with AF. Vitamin K antagonist (eg, warfarin) has been recommended for stroke prevention among patients with nonvalvular AF (NVAF) for several decades. Direct oral anticoagulants (DOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, are effective and safe alternatives to warfarin for stroke prevention in patients with NVAF.[4](#jah34541-bib-0004){ref-type="ref"}, [5](#jah34541-bib-0005){ref-type="ref"}, [6](#jah34541-bib-0006){ref-type="ref"}, [7](#jah34541-bib-0007){ref-type="ref"} The global ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study evaluated the efficacy and safety of rivaroxaban 20 mg/d (15 mg/d if moderate renal impairment) compared with warfarin therapy for stroke prevention in patients with NVAF. The results indicated that rivaroxaban was associated with comparable efficacy and safety to warfarin in patients with NVAF.[5](#jah34541-bib-0005){ref-type="ref"} J‐ROCKET AF (Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) was a similar but much smaller study comparing the efficacy and safety of rivaroxaban 15 mg/d (10 mg/d if moderate renal impairment) and warfarin in Japanese patients with NVAF, which showed a comparable risk of major bleeding and a strong trend for the reduction in the risk of stroke/systemic embolism with rivaroxaban 15/10 mg/d versus warfarin.[8](#jah34541-bib-0008){ref-type="ref"} Of note, Taiwan is the only country that approved either a standard‐dose regimen (20/15 mg/d), following the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) dosage criteria, or low‐dose regimen (15/10 mg/d), following the J‐ROCKET AF dosage criteria, for stroke prevention in patients with NVAF around the world. However, 2 different dosage recommendations of rivaroxaban have not been previously compared. Also, data about the comparisons of rivaroxaban at the dose following J‐ROCKET AF and warfarin in daily practice outside Japan were limited. In the present study, we aimed to compare the effectiveness and safety of rivaroxaban following ROCKET AF (20/15 mg/d) and J‐ROCKET AF (15/10 mg/d) among Asians with NVAF. In addition, the safety and efficacy of warfarin and rivaroxaban at either dosage criteria were also compared.

Methods {#jah34541-sec-0009}
=======

Study Population {#jah34541-sec-0010}
----------------

The data that support the findings of this study are available from the corresponding author upon reasonable request. This present study was approved by the institutional review board of the Chang Gung Medical Foundation. In the retrospective cohort study, patient data were obtained from the Chang Gung Memorial Hospital System, which is the largest healthcare provider in Taiwan, which comprises 3 major teaching hospitals and 4 tertiary care medical centers. The healthcare provider has a total of 10 050 beds and admits ≈280 000 patients per year.[9](#jah34541-bib-0009){ref-type="ref"} Informed consent was waived because the original identification number of each patient in the present study is encrypted and deidentified to protect patient privacy by using a consistent encrypting procedure. This study is based in part on data from the Chang Gung Research Database provided by Chang Gung Memorial Hospital. The interpretation and conclusions contained herein do not represent the position of Chang Gung Memorial Hospital.

Study Design {#jah34541-sec-0011}
------------

The study design flowchart and patient enrollment are shown in Figure [1](#jah34541-fig-0001){ref-type="fig"}. From June 1, 2012, to December 31, 2017, 18 591 patients diagnosed with AF (*International Classification of Diseases, Ninth Revision Clinical Modification* \[*ICD‐9‐CM*\] codes \[427.31\] or *ICD‐10‐CM codes* \[I48\]) taking at least 1 prescription filled for oral anticoagulant (edoxaban, apixaban, rivaroxaban, dabigatran, or warfarin) were identified. The index date was defined as the first date of prescribing DOACs or warfarin. The follow‐up period was defined as the duration from the index date until the occurrence of study outcomes or until the end date of the study period (December 31, 2017), whichever came first. To establish a cohort of patients with NVAF who took an oral anticoagulant for the primary purpose of stroke prevention, patients were excluded if they had diagnoses indicating venous thromboembolism (deep vein thrombosis or pulmonary embolism) (n=74) or valvular AF (mitral stenosis or history of valvular surgery), or required joint replacement therapy (n=236) within 6 months before the index date. Patients with end‐stage renal disease (n=83) were also excluded because NOACs are contraindicated in such patients in Taiwan.

![Enrollment of patients with nonvalvular atrial fibrillation (NVAF). There were 2320 and 842 patients with NVAF with estimated glomerular filtration rate (eGFR) ≥50 mL/min per 1.73 m^2^ and eGFR \<50 mL/min per 1.73 m^2^ taking rivaroxaban, respectively, enrolled in this study from June 1, 2012, to December 31, 2017. Among the 2320 patients with eGFR ≥50 mL/min per 1.73 m^2^, there were 384 and 1936 patients following the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) (20 mg/d) and J‐ROCKET AF (Japanese ROCKET AF) (15 mg/d) dosage criteria, respectively. Among the 842 patients with eGFR \<50 mL/min per 1.73 m^2^, there were 422 and 420 patients following the ROCKET AF (15 mg/d) and J‐ROCKET AF (10 mg/d) dosage criteria, respectively. AF indicates atrial fibrillation.](JAH3-8-e013053-g001){#jah34541-fig-0001}

We specifically focused on rivaroxaban in the present study, and patients taking the other 3 DOACs (n=5636) anytime during the entire study period were excluded. The study identified a total of 4421 patients taking rivaroxaban for stroke prevention whose baseline renal functions were available. Of these, 1225 patients (27.7%) who were prescribed 10 mg of rivaroxaban once daily were excluded. We also excluded 34 patients with an estimated glomerular filtration rate (eGFR) \<50 mL/min per 1.73 m^2^ who took rivaroxaban 20 mg once daily. Finally, 3162 patients were eligible for this study and were divided into 2 subgroups: (1) patients with an eGFR ≥50 mL/min per 1.73 m^2^ (n=2320), and (2) patients with an eGFR \<50 mL/min per 1.73 m^2^ (n=842). During the same study period, a total of 2053 patients with AF treated with warfarin for stroke prevention were also identified.

Of note, the present study was performed in an intention‐to‐treat design, similar to most trials, where each study group was included in the statistical analysis and analyzed according to the group they were originally assigned, regardless of what treatment (if any) they received or changed. For example, patients taking rivaroxaban 20 mg/d with a baseline eGFR ≥50 mL/min per 1.73 m^2^ would still be categorized as the ROCKET AF dosing group, even though the daily doses of rivaroxaban were shifted from 20 mg to 15 mg or 10 mg later because of a decline in renal function or physician\'s intention during the following‐up period, and vice versa. Indeed, for 384 patients originally taking rivaroxaban at a daily dose of 20 mg, the dosage was shifted to 15 mg/d and 10 mg/d in 64 and 48 patients, respectively. For 2358 patients originally taking rivaroxaban at a daily dose of 15 mg, the dosage was shifted to 20 mg/d and 10 mg/d in 38 and 339 patients, respectively. For 420 patients originally taking rivaroxaban at a daily dose of 10 mg, the dosage was shifted 15 mg/d in 20 patients and none of them increased the dosage to 20 mg.

Study Outcomes {#jah34541-sec-0012}
--------------

Six study outcomes were assessed to investigate the effectiveness and safety of rivaroxaban, including ischemic stroke/systemic embolism (IS/SE), acute myocardial infarction (AMI), all‐cause mortality, intracranial hemorrhage (ICH), major gastrointestinal bleeding (GIB), and all major bleeding events. All study outcomes were defined on the basis of the discharge diagnosis to avoid misclassification. ICH was defined with the use of codes for atraumatic hemorrhage. Major GIB was defined as a hospitalized primary diagnosis indicating bleeding in the gastrointestinal tract. All major bleeding events were defined as the total number of hospitalized events of ICH, major GIB, and other sites of critical bleeding. The diagnosis codes used in Chang Gung Memorial Hospital System were shifted from *ICD‐9‐CM* to *ICD‐10‐CM* after January 1, 2016. The *ICD‐9‐CM* and *ICD‐10‐CM* codes used to identify the study outcomes, and the baseline covariates are summarized in Table [S1](#jah34541-sup-0001){ref-type="supplementary-material"}.

Covariates {#jah34541-sec-0013}
----------

Baseline covariates referred to any claim record with the above diagnoses or medication codes before the index date. Bleeding history was confined to events within 6 months preceding the index date. A history of any prescription medicine was confined to medications taken at least once within 3 months preceding the index date. Important laboratory data, including serum hemoglobin, platelet count, eGFR, and alanine aminotransferase, were based on the measurements performed within 6 months of the index date. The CHA~2~DS~2~‐VASc score (congestive heart failure, hypertension, age 75 years or older for 2 points, diabetes mellitus, previous stroke or transient ischemic attack for 2 points, vascular disease, age 65--74 years, and female) was computed to represent the predicted risk of IS/SE in patients with AF.[10](#jah34541-bib-0010){ref-type="ref"} The HAS‐BLED score (hypertension, abnormal renal/liver function, stroke, bleeding history, labile international normalized ratio \[INR\], age 65 years or older, and antiplatelet drug/alcohol use) was adopted to represent the risk of bleeding in patients with AF treated with oral anticoagulants.[11](#jah34541-bib-0011){ref-type="ref"}

Statistical Analysis {#jah34541-sec-0014}
--------------------

Data were presented as mean and SD for continuous variables and as proportions for categorical variables. Unpaired 2‐tailed *t* test was used to compare the differences between continuous values. Chi‐square test was used to compare the differences between nominal variables. Logistic regression analysis was performed to identify factors associated with the prescriptions of rivaroxaban following either ROCKET AF or J‐ROCKET AF dosage criteria. Crude incidence rates were computed as the total number of study outcomes during the follow‐up time divided by person‐years at risk. Cox proportional hazards regression was used to compare the risk of events between ROCKET AF and J‐ROCKET AF dosage criteria in patients with an eGFR ≥50 mL/min per 1.73 m^2^ and \<50 mL/min per 1.73 m^2^ separately. The covariates included in the Cox regression models were variables that differed significantly between patients following ROCKET AF and J‐ROCKET AF dosage criteria (*P*\<0.05). The comparisons between rivaroxaban and warfarin were performed using Cox regression analysis in the same way. Statistical significance was defined as *P*\<0.05. All analyses were conducted using SAS 9.2 (SAS Institute).

Results {#jah34541-sec-0015}
=======

This study identified a total of 2320 and 842 consecutive rivaroxaban users with an eGFR ≥50 mL/min per 1.73 m^2^ and eGFR \<50 mL/min per 1.73 m^2^, respectively. Among patients with an eGFR ≥50 mL/min per 1.73 m^2^, 384 (16.6%) and 1936 (83.4%) of them followed the ROCKET AF (20 mg/d) and J‐ROCKET AF (15 mg/d) dosage criteria, respectively. Among patients with an eGFR \<50 mL/min per 1.73 m^2^, 422 (50.1%) and 420 (49.9%) of them followed the ROCKET AF (15 mg/d) and J‐ROCKET AF (10 mg/d) dosage criteria, respectively (Figure [1](#jah34541-fig-0001){ref-type="fig"}). The mean drug adherence rate of rivaroxaban, calculated based on proportion of days covered with rivaroxaban during the entire follow‐up period for each patient, was 69%.

Rivaroxaban Versus Warfarin {#jah34541-sec-0016}
---------------------------

The baseline characteristics of patients taking warfarin and rivaroxaban following either ROCKET AF or J‐ROCKET AF dose criteria are shown in Table [1](#jah34541-tbl-0001){ref-type="table"}. For patients taking warfarin, the average time in therapeutic ranges (TTRs) of INRs targeted at 2.0 to 3.0 or 1.5 to 2.5 were 22.2±26.1% and 43.2±34.0%, respectively. The patients in the rivaroxaban groups following either ROCKET AF (n=806) or J‐ROCKET AF (n=2356) dosage criteria were older and had more comorbidities and higher CHA~2~DS~2~‐VASc and HAS‐BLED scores compared with the warfarin group (n=2054). The prevalence rates of concomitant use of antiplatelet agents were lower among patients taking rivaroxaban compared with those taking warfarin (31.1% in ROCKET AF, 29.5% in J‐ROCKET AF, and 35.1% in warfarin groups). The baseline eGFRs were 59.5±26.7, 72.3±27.9, and 63.5±37.6 mL/min per 1.73 m^2^ for patients taking rivaroxaban following ROCKET AF, J‐ROCKET AF dosage criteria, and those taking warfarin, respectively. At the end of the study, the average declines in eGFR were 1.2±20.1, 2.5±25.5, and 3.9±24.8 mL/min per 1.73 m^2^ for ROCKET AF, J‐ROCKET AF, and warfarin groups, respectively (Table [1](#jah34541-tbl-0001){ref-type="table"}). The median follow‐up periods for the ROCKET AF, J‐ROCKET AF, and warfarin groups were 2.66, 2.48, and 2.35 years, respectively.

###### 

Baseline Characteristics of Patients With NVAF Taking Rivaroxaban Following the ROCKET AF or J‐ROCKET AF Dose Criteria Versus Patients Taking Warfarin

                                             ROCKET AF Criteria 20/15 mg/d (n=806)   J‐ROCKET AF Criteria 15/10 mg/d (n=2356)   Warfarin (n=2053)   *P* Value ROCKET AF vs Warfarin   *P* Value J‐ROCKET AF vs Warfarin
  ------------------------------------------ --------------------------------------- ------------------------------------------ ------------------- --------------------------------- -----------------------------------
  Age, y                                     72.44±10.67                             73.85±9.83                                 67.03±12.75         \<0.001                           \<0.001
  Women, No. (%)                             311 (38.6)                              975 (41.4)                                 859 (41.8)          0.111                             0.759
  CHA~2~DS~2~‐VASc score                     3.61±1.67                               3.49±1.60                                  2.71±1.84           \<0.001                           \<0.001
  HAS‐BLED score                             2.94±1.24                               2.80±1.19                                  2.34±1.46           \<0.001                           \<0.001
  History, No. (%)                                                                                                                                                                    
  Chronic lung disease                       240 (29.8)                              706 (30.0)                                 484 (23.6)          0.001                             \<0.001
  Chronic liver disease                      144 (17.9)                              500 (21.2)                                 417 (20.3)          0.138                             0.457
  Congestive heart failure                   102 (12.7)                              227 (9.6)                                  247 (12.0)          0.647                             0.010
  Hypertension                               647 (80.3)                              1809 (76.8)                                1351 (65.8)         \<0.001                           \<0.001
  Hyperlipidemia                             378 (46.9)                              1073 (45.5)                                746 (36.3)          \<0.001                           \<0.001
  Diabetes mellitus                          338 (41.9)                              849 (36.0)                                 693 (33.8)          \<0.001                           0.113
  Previous stroke                            178 (22.1)                              409 (17.4)                                 146 (7.1)           \<0.001                           \<0.001
  Previous TIA                               20 (2.5)                                42 (1.8)                                   28 (1.4)            0.036                             0.267
  Ischemic heart disease                     97 (12.0)                               258 (11.0)                                 268 (13.1)          0.462                             0.032
  Gout                                       186 (23.1)                              402 (17.1)                                 379 (18.5)          0.005                             0.225
  Peripheral artery disease                  3 (0.4)                                 3 (0.1)                                    8 (0.4)             1.000                             0.082
  Malignancy                                 110 (13.6)                              376 (16.0)                                 292 (14.2)          0.69                              0.109
  Laboratory data                                                                                                                                                                     
  Hemoglobin, g/dL                           13.01±2.29                              13.05±2.05                                 12.39±2.41          \<0.001                           \<0.001
  Platelet, ×1000/Ul                         199.90±66.04                            197.84±66.24                               196.45±74.49        0.27                              0.529
  Baseline eGFR, mL/min per 1.73 m^2^        59.54±26.72                             72.26±27.88                                63.53±37.59         0.006                             \<0.001
  Changes of eGFR, mL/min per 1.73 m^2^      −1.16±20.11                             −2.47±25.54                                −3.88±24.79         0.006                             0.064
  ALT, U/L                                   27.90±33.92                             28.98±94.90                                34.16±82.16         0.041                             0.061
  Medications, No. (%)                                                                                                                                                                
  Concomitant APT                            251 (31.1)                              695 (29.5)                                 720 (35.1)          0.0459                            \<0.001
  NSAIDs                                     126 (15.6)                              316 (13.4)                                 252 (12.3)          0.017                             0.261
  PPIs                                       96 (11.9)                               246 (10.4)                                 286 (13.9)          0.153                             \<0.001
  ACEIs/ARBs                                 506 (62.8)                              1332 (56.5)                                1042 (50.8)         \<0.001                           \<0.001
  Loop diuretics                             254 (31.5)                              660 (28.0)                                 725 (35.3)          0.054                             \<0.001
  Amiodarone                                 172 (21.3)                              461 (19.6)                                 548 (26.7)          0.003                             \<0.001
  Dronedarone                                23 (2.9)                                75 (3.2)                                   56 (2.7)            0.853                             0.374
  Quinidine                                  3 (0.4)                                 3 (0.1)                                    8 (0.4)             1.000                             0.082
  β‐Blockers                                 495 (61.4)                              1347 (57.2)                                1246 (60.7)         0.722                             0.018
  Diltiazem                                  135 (16.7)                              447 (19.0)                                 364 (17.7)          0.534                             0.288
  Verapamil                                  35 (4.3)                                107 (4.5)                                  86 (4.2)            0.855                             0.568
  Digoxin                                    140 (17.4)                              453 (19.2)                                 417 (20.3)          0.074                             0.367
  Statins                                    297 (36.8)                              802 (34.0)                                 532 (25.9)          \<0.001                           \<0.001
  Azithromycin/clarithromycin/erythromycin   11 (1.4)                                41 (1.7)                                   32 (1.6)            0.701                             0.637
  Itraconazole                               0 (0.0)                                 3 (0.1)                                    1 (0.0)             1.000                             0.628
  Cyclosporine                               1 (0.1)                                 4 (0.2)                                    2 (0.1)             1.000                             0.692

ACEIs indicates angiotensin‐converting enzyme inhibitors; ALT, alanine aminotransferase; APT, antiplatelet agent; ARBs, angiotensin II receptor antagonists; CHA~2~DS~2~‐VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female; eGFR, estimated glomerular filtration rate; HAS‐BLED, hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, age 65 years or older, and antiplatelet drug or alcohol use; J ROCKET AF, Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; NSAIDs, nonsteroidal anti‐inflammatory drugs; NVAF, nonvalvular atrial fibrillation; PPIs, proton pump inhibitors; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; TIA, transient ischemic attack.

Patients taking rivaroxaban following either ROCKET AF or J‐ROCKET AF dosage criteria showed a comparable risk of IS/SE and a lower risk of AMI, mortality, ICH, and all major bleeding than those taking warfarin after the adjustments for baseline differences (Figure [2](#jah34541-fig-0002){ref-type="fig"} and Table [S2](#jah34541-sup-0001){ref-type="supplementary-material"}). Among 229 patients who experienced major bleeding, the average blood pressures were 141.8±25.8 mm Hg (142.4±24.9 mm Hg for patients with an eGFR ≥50 mL/min per 1.73 m^2^ and 141.6±24.2 mm Hg for those with an eGFR \<50 mL/min per 1.73 m^2^) at the time when major bleeding occurred. Compared with patients taking warfarin with the top quartile of individual TTR (mean 61.1% for the range of INR between 2.0 and 3.0), patients taking rivaroxaban following either ROCKET AF or J‐ROCKET AF dosage criteria showed a comparable risk of IS/SE and a lower risk of mortality, ICH, and all major bleeding, which were generally consistent with the principal analyses (Figure [S1](#jah34541-sup-0001){ref-type="supplementary-material"}).

![Forest plot of hazard ratio (HR) and 95% CI for patients with nonvalvular atrial fibrillation taking rivaroxaban following the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) dosage criteria or J‐ROCKET AF (Japanese ROCKET AF) dosage criteria vs patients taking warfarin. Patients taking rivaroxaban following either the ROCKET AF (20/15 mg/d) or J‐ROCKET AF (15/10 mg/d) dosage criteria showed a comparable risk of ischemic stroke or systemic embolism (IS/SE) and a lower risk of acute myocardial infarction (AMI), mortality, intracranial hemorrhage (ICH), and all major bleeding than patients taking warfarin after baseline covariate adjustment. GIB indicates gastrointestinal bleeding.](JAH3-8-e013053-g002){#jah34541-fig-0002}

Baseline Characteristics of Patients Following ROCKET AF Versus J‐ROCKET AF Dosage Criteria {#jah34541-sec-0017}
-------------------------------------------------------------------------------------------

The baseline characteristics of patients following ROCKET AF versus J‐ROCKET AF dosage criteria are shown in Table [2](#jah34541-tbl-0002){ref-type="table"}. In general, patients following the ROCKET AF dosage criteria were younger than those following the J‐ROCKET AF dosage criteria (both *P*\<0.001). Patients following the ROCKET AF dosage criteria had a higher prevalence of stroke history than those following the J‐ROCKET AF dose criteria in patients with an eGFR \<50 mL/min per 1.73 m^2^ (24.6% versus 13.3%, *P*\<0.001). The prevalence rates of concomitant use of antiplatelet agents did not differ significantly between the 2 groups. Of note, patients following the ROCKET AF dosage criteria had a comparable eGFR to those following the J‐ROCKET AF recommendation in patients with an eGFR ≥50 mL/min per 1.73 m^2^ (81.54±21.88 versus 79.75±24.69 mL/min per 1.73 m^2^, *P*=0.187), whereas patients following the ROCKET AF dose criteria had a higher eGFR than those following the J‐ROCKET AF recommendation in patients with an eGFR \<50 mL/min per 1.73 m^2^ (39.51±9.25 versus 37.70±9.84 mL/min per 1.73 m^2^, *P*=0.006). The changes of eGFRs at the end of the follow‐up were similar between the ROCKET AF and J‐ROCKET AF groups.

###### 

Baseline Characteristics of Patients With NVAF With Normal or Impaired Renal Function Taking Rivaroxaban Following the ROCKET AF or the J‐ROCKET AF Dosage Criteria

                                             eGFR ≥50 mL/min per 1.73 m^2^ (n=2320)   eGFR \<50 mL/min per 1.73 m^2^ (n=842)                                           
  ------------------------------------------ ---------------------------------------- ---------------------------------------- --------- -------------- -------------- ---------
  Age, y                                     68.71±10.46                              72.65±9.80                               \<0.001   75.84±9.69     79.34±7.93     \<0.001
  Women, No. (%)                             120 (31.2)                               774 (40.0)                               0.001     191 (45.3)     201 (47.9)     0.450
  CHA~2~DS~2~‐VASc score                     3.00±1.60                                3.34±1.59                                \<0.001   4.16±1.52      4.18±1.43      0.846
  HAS‐BLED score                             2.51±1.16                                2.68±1.17                                0.009     3.33±1.19      3.34±1.11      0.96
  History, No. (%)                                                                                                                                                     
  Chronic lung disease                       98 (25.5)                                540 (27.9)                               0.342     142 (33.6)     166 (39.5)     0.077
  Chronic liver disease                      66 (17.2)                                401 (20.7)                               0.116     78 (18.5)      99 (23.6)      0.070
  Congestive heart failure                   33 (8.6)                                 151 (7.8)                                0.599     69 (16.4)      76 (18.1)      0.503
  Hypertension                               276 (71.9)                               1452 (75.0)                              0.199     371 (87.9)     357 (85.0)     0.216
  Hyperlipidemia                             168 (43.8)                               855 (44.2)                               0.882     210 (49.8)     218 (51.9)     0.534
  Diabetes mellitus                          134 (34.9)                               634 (32.7)                               0.414     204 (48.3)     215 (51.2)     0.408
  Previous stroke                            74 (19.3)                                353 (18.2)                               0.632     104 (24.6)     56 (13.3)      \<0.001
  Previous TIA                               5 (1.3)                                  32 (1.7)                                 0.616     15 (3.6)       10 (2.4)       0.316
  Ischemic heart disease                     37 (9.6)                                 192 (9.9)                                0.866     60 (14.2)      66 (15.7)      0.543
  Gout                                       61 (15.9)                                271 (14.0)                               0.335     125 (29.6)     131 (31.2)     0.621
  Peripheral artery disease                  3 (0.8)                                  2 (0.1)                                  0.035     0 (0.0)        1 (0.2)        0.499
  Malignancy                                 37 (9.6)                                 301 (15.5)                               0.003     73 (17.3)      75 (17.9)      0.831
  Laboratory data                                                                                                                                                      
  Hemoglobin, g/dL                           13.73±2.14                               13.30±1.98                               \<0.001   12.38±2.24     11.97±2.03     0.006
  Platelet, ×1000/μL                         200.26±65.41                             199.97±66.05                             0.941     199.60±66.66   188.49±66.34   0.019
  Baseline eGFR, mL/min per 1.73 m^2^        81.54±21.88                              79.75±24.69                              0.187     39.51±9.25     37.70±9.84     0.006
  Changes of eGFR, mL/min per 1.73 m^2^      −3.91±23.77                              −3.36±27.01                              0.707     1.35±15.69     1.63±16.60     0.801
  ALT, U/L                                   28.86±41.99                              29.61±103.78                             0.893     27.07±24.80    26.17±32.81    0.659
  Medications, No. (%)                                                                                                                                                 
  Concomitant APT                            106 (27.6)                               543 (28.1)                               0.860     145 (34.4)     152 (36.2)     0.578
  NSAIDs                                     49 (12.8)                                250 (12.9)                               0.935     77 (18.2)      66 (15.7)      0.328
  PPIs                                       32 (8.3)                                 188 (9.7)                                0.4       64 (15.2)      58 (13.8)      0.576
  ACEIs/ARBs                                 221 (57.6)                               1063 (54.9)                              0.341     285 (67.5)     269 (64.0)     0.286
  Loop diuretics                             87 (22.7)                                455 (23.5)                               0.72      167 (39.6)     205 (48.8)     0.007
  Amiodarone                                 70 (18.2)                                364 (18.8)                               0.793     102 (24.2)     97 (23.1)      0.713
  Dronedarone                                6 (1.6)                                  52 (2.7)                                 0.198     17 (4.0)       23 (5.5)       0.323
  Quinidine                                  1 (0.3)                                  1 (0.1)                                  0.304     2 (0.5)        2 (0.5)        1.000
  β‐Blocker                                  243 (63.3)                               1090 (56.3)                              0.012     252 (59.7)     257 (61.2)     0.662
  Diltiazem                                  65 (16.9)                                386 (19.9)                               0.173     70 (16.6)      61 (14.5)      0.409
  Verapamil                                  23 (6.0)                                 93 (4.8)                                 0.33      12 (2.8)       14 (3.3)       0.681
  Digoxin                                    65 (16.9)                                366 (18.9)                               0.363     75 (17.8)      87 (20.7)      0.279
  Statins                                    139 (36.2)                               629 (32.5)                               0.158     158 (37.4)     173 (41.2)     0.265
  Azithromycin/clarithromycin/erythromycin   2 (0.5)                                  35 (1.8)                                 0.066     9 (2.1)        6 (1.4)        0.440
  Itraconazole                               0 (0.0)                                  2 (0.1)                                  1.000     0 (0.0)        1 (0.2)        0.499
  Cyclosporine                               0 (0.0)                                  3 (0.2)                                  1.000     1 (0.2)        1 (0.2)        1.000

ACEIs indicates angiotensin‐converting enzyme inhibitors; ALT, alanine aminotransferase; APT, antiplatelet agent; ARBs, angiotensin II receptor antagonists; CHA~2~DS~2~‐VASc, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female; eGFR, estimated glomerular filtration rate; HAS‐BLED, hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio, age 65 years or older, and antiplatelet drug or alcohol use; J ROCKET AF, Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; NSAIDs, nonsteroidal anti‐inflammatory drugs; NVAF, nonvalvular atrial fibrillation; PPIs, proton pump inhibitors; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; TIA, transient ischemic attack.

Patients With an eGFR ≥50 mL/min per 1.73 m^2^ {#jah34541-sec-0018}
----------------------------------------------

For patients with an eGFR ≥50 mL/min per 1.73 m^2^, older age and presence of malignancy were independent factors associated with the prescriptions of rivaroxaban following J‐ROCKET AF dosage criteria (15 mg/d), while the presence of peripheral artery disease was associated with the prescriptions following ROCKET AF dosage criteria (20 mg/d) (Table [3](#jah34541-tbl-0003){ref-type="table"} \[upper panel\]). Figure [3](#jah34541-fig-0003){ref-type="fig"} and Table [S3](#jah34541-sup-0001){ref-type="supplementary-material"} (upper panel) show the adjusted hazard ratios and 95% CIs of the efficacy and safety outcomes for ROCKET AF (20 mg/d) versus J‐ROCKET AF (15 mg/d) dosage criteria among patients with an eGFR ≥50 mL/min per 1.73 m^2^. Compared with J‐ROCKET AF (15 mg/d) dosage criteria (n=1936), ROCKET AF (20 mg/d) dosage criteria (n=384) was associated with a similar risk of IS/SE, AMI, mortality, ICH, major GIB, and all major bleeding after adjustments for baseline differences.

###### 

Factors for Patients Choosing to Follow the ROCKET AF or the J‐ROCKET AF Dosage Criteria

                                           ROCKET AF vs J‐ROCKET AF Univariate OR   ROCKET AF vs J‐ROCKET AF Multivariate OR                        
  ---------------------------------------- ---------------------------------------- ------------------------------------------ -------------------- ---------
  eGFR ≥50 mL/min per 1.73 m^2^ (n=2320)                                                                                                            
  Age                                      0.96 (0.95--0.97)                        \<0.001                                    0.97 (0.95--0.98)    \<0.001
  Women                                    0.68 (0.54--0.86)                        0.001                                                           
  CHA~2~DS~2~‐VASc score                   0.87 (0.81--0.93)                        \<0.001                                                         
  Peripheral artery disease                7.61 (1.27--45.72)                       0.026                                      8.82 (1.43--54.40)   0.019
  Malignancy                               0.58 (0.40--0.83)                        0.003                                      0.62 (0.42--0.91)    0.014
  Hemoglobin, per g/dL                     1.12 (1.05--1.18)                        \<0.001                                                         
  Use of β‐blockers                        1.34 (1.07--1.68)                        0.012                                                           
  eGFR \<50 mL/min per 1.73 m^2^ (n=842)                                                                                                            
  Age                                      0.96 (0.94--0.97)                        \<0.001                                    0.95 (0.94--0.97)    \<0.001
  Stroke history                           2.13 (1.49--3.04)                        \<0.001                                    2.28 (1.56--3.33)    \<0.001
  Hemoglobin, per g/dL                     1.09 (1.03--1.17)                        0.007                                                           
  Platelet, per 10 000/μL                  1.02 (1.00--1.03)                        0.020                                      1.03 (1.01--1.05)    0.018
  eGFR, per mL/min per 1.73 m^2^           1.02 (1.01--1.03)                        0.007                                                           
  Use of loop diuretics                    0.69 (0.52--0.90)                        0.007                                                           

CHA~2~DS~2~‐VASc indicates congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female; eGFR, estimated glomerular filtration rate; J ROCKET AF, Japanese ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; OR, odds ratio; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.

![Forest plot of hazard ratio (HR) and 95% CI for rivaroxaban following the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) dosage criteria vs J‐ROCKET AF (Japanese ROCKET AF) dosage criteria in patients with nonvalvular atrial fibrillation with estimated glomerular filtration rate (eGFR) ≥50 mL/min per 1.73 m^2^ and eGFR \<50 mL/min per 1.73 m^2^. For patients with eGFR \>50 mL/min per 1.73 m^2^, following the ROCKET AF dosage criteria (20 mg/d) was associated with a comparable risk of ischemic stroke or systemic embolism (IS/SE) and major bleeding to following the J‐ROCKET AF dosage criteria (15 mg/d) after baseline covariate adjustment. For patients with eGFR \<50 mL/min per 1.73 m^2^, following the ROCKET AF dosage criteria (15 mg/d) was associated with a higher risk of major bleeding than following the J‐ROCKET AF dosage criteria (10 mg/d) after baseline covariate adjustment. AMI indicates acute myocardial infarction; GIB, gastrointestinal bleeding; ICH, intracranial hemorrhage.](JAH3-8-e013053-g003){#jah34541-fig-0003}

Patients With an eGFR \<50 mL/min per 1.73 m^2^ {#jah34541-sec-0019}
-----------------------------------------------

For patients with an eGFR \<50 mL/min per 1.73 m^2^, older age and low platelet count were independent factors associated with the prescriptions following the J‐ROCKET AF dosage criteria, whereas previous stroke history was the independent factor associated with the prescriptions following ROCKET AF dosage criteria (Table [3](#jah34541-tbl-0003){ref-type="table"} \[lower panel\]). Figure [3](#jah34541-fig-0003){ref-type="fig"} and Table [S3](#jah34541-sup-0001){ref-type="supplementary-material"} (lower panel) show the adjusted hazard ratios and 95% CIs of outcomes for ROCKET AF (15 mg/d) versus J‐ROCKET AF (10 mg/d) dosage criteria among patients with an eGFR \<50 mL/min per 1.73 m^2^. Compared with J‐ROCKET AF (10 mg/d) dosage criteria (n=420), ROCKET AF (15 mg/d) dosage criteria (n=422) was associated with a higher risk of all major bleeding (adjusted hazard ratio, 2.70; 95% CI, 1.03--7.13 \[*P*=0.0445\]) with no significant differences in the risk of IS/SE, AMI, mortality, ICH, and major GIB.

Discussion {#jah34541-sec-0020}
==========

Main Findings {#jah34541-sec-0021}
-------------

This is the first study to directly compare the effectiveness and safety between standard‐dose (20/15 mg/d) and low‐dose (15/10 mg/d) rivaroxaban among Asians with NVAF in real‐world practice. This is because Taiwan is the only country that approved either ROCKET AF or J‐ROCKET AF dosage criteria for stroke prevention in patients with NVAF. The main findings of this study are as follows: (1) Clinical physicians chose to prescribe rivaroxaban following the J‐ROCKET AF rather than ROCKET AF dosage criteria for most Asian AF patients (75%) despite the approval of both dosages for stroke prevention in Taiwan. (2) Use of rivaroxaban following either ROCKET AF or J‐ROCKET AF dosage criteria was associated with a similar risk of IS/SE and a significantly lower risk of bleeding compared with warfarin. (3) Older age and presence of malignancy were independent factors associated with prescriptions of rivaroxaban following J‐ROCKET AF dosage criteria (15 mg/d) for patients with an eGFR ≥50 mL/min per 1.73 m^2^, whereas older age and low platelet count were independent factors associated with the prescriptions following the J‐ROCKET AF dosage criteria (10 mg/d) in patients with an eGFR \<50 mL/min per 1.73 m^2^. On the contrary, the presence of peripheral artery disease was associated with the prescriptions following ROCKET AF dosage criteria (20 mg/d) for patients with an eGFR ≥50 mL/min per 1.73 m^2^, whereas previous stroke history was the independent factor associated with the prescriptions following ROCKET AF dosage criteria (15 mg/d) in patients with an eGFR \<50 mL/min per 1.73 m^2^. (4) J‐ROCKET AF (15 mg/d) dosage criteria was as effective as ROCKET AF (20 mg/d) dose criteria for the prevention of IS/SE among patients with either an eGFR ≥ or \<50 mL/min per 1.73 m^2^. For patients with an eGFR \<50 mL/min per 1.73 m^2^, ROCKET AF (15 mg/d) dosage criteria was associated with a significantly higher risk of major bleeding compared with J‐ROCKET AF (10 mg/d) dosage criteria.

Low‐Dose DOACs in Stroke Prevention {#jah34541-sec-0022}
-----------------------------------

Recent real‐world data demonstrated a high prevalence of prescriptions of DOACs at a low dose in patients with NVAF worldwide.[12](#jah34541-bib-0012){ref-type="ref"}, [13](#jah34541-bib-0013){ref-type="ref"}, [14](#jah34541-bib-0014){ref-type="ref"}, [15](#jah34541-bib-0015){ref-type="ref"} In the present study, we also observed a high percentage (75%) of patients taking rivaroxaban at a lower dose by following the J‐ROCKET AF dosage criteria, which was triggered by older age, presence of underlying malignancy, and low platelet count. These findings suggest that Asian physicians are concerned about the risk of bleeding with oral anticoagulants, and therefore, prefer to choose a lower dose for Asian patients with AF.

Of note, inappropriate prescriptions of low‐dose DOACs without following the "labelling" recommendation may result in more thromboembolic events, while failing to reduce the risk of major bleeding.[12](#jah34541-bib-0012){ref-type="ref"} These findings highlight the importance of prescribing DOACs at an "on‐label" dose for stroke prevention. However, a debate about the dose of rivaroxaban is whether J‐ROCKET AF dosage criteria should be regarded as an "on‐label" dosage for Asian patients with AF. The existence of the argument is because the J‐ROCKET AF dosage criteria was only supported by the J‐ROCKET AF study, with a much smaller sample size than that of the ROCKET AF trial (n=1280 versus 14 264).[5](#jah34541-bib-0005){ref-type="ref"}, [8](#jah34541-bib-0008){ref-type="ref"} In addition, the target range of the INR in the J‐ROCKET AF study (1.6--2.6 for patients aged ≥70 years and 2.0--3.0 for those aged \<70 years) is different from that of the ROCKET AF study (2.0--3.0 regardless of patient age). In the present study, we demonstrated that rivaroxaban at a dose following either ROCKET AF or J‐ROCKET AF dosage criteria was as effective as warfarin for the prevention of thromboembolic events and was associated with a significantly lower risk of ICH and major bleeding. Rivaroxaban at the J‐ROCEKT AF dosage in particular was associated with a lower risk of major GIB compared with warfarin. These findings provide real‐world data supporting the use of rivaroxaban following J‐ROCKET AF dosage criteria as an alternative choice to warfarin for stroke prevention. However, more prospective and randomized studies are necessary to investigate this issue and confirm our findings.

Different Dosage Criteria of Rivaroxaban for Asians---ROCKET AF Versus J‐ROCKET AF {#jah34541-sec-0023}
----------------------------------------------------------------------------------

Previous studies have shown that Asian patients with AF have a higher risk of ICH compared with non‐Asians treated with DOACs, suggesting that Asians are more prone to bleeding.[16](#jah34541-bib-0016){ref-type="ref"}, [17](#jah34541-bib-0017){ref-type="ref"}, [18](#jah34541-bib-0018){ref-type="ref"}, [19](#jah34541-bib-0019){ref-type="ref"} Therefore, clinical physicians in Asia may tend to prescribe a lower dose of DOACs for Asian patients in daily practice. In fact, J‐ROCKET dosage criteria is the only dosage regimen approved in Japan for stroke prevention in AF. In addition, even in South Korea where J‐ROCKET dosage criteria was not approved, a daily dosage of rivaroxaban at 15 mg rather than 20 mg accounted for almost 60% of the prescriptions.[20](#jah34541-bib-0020){ref-type="ref"} Therefore, it is important to understand the safety and effectiveness of rivaroxaban following J‐ROCKET AF dosage criteria compared with that of ROCKET AF. In the present study, we demonstrated that the risk of ischemic stroke did not differ significantly between J‐ROCKET AF and ROCKET AF dosage criteria. For patients with an eGFR ≥50 mL/min per 1.73 m^2^, ROCKET AF dosage was not associated with a higher risk of ICH, major GIB, or all major bleeding compared with J‐ROCKET dosage. Among patients with an eGFR \<50 mL/min per 1.73 m^2^, the risk of major bleeding was lower in favor of J‐ROCKET AF criteria. Our findings provided good insight into the performance of rivaroxaban following J‐ROCKET criteria, which suggested that it may serve as an alternative to ROCKET AF criteria, especially for patients with an eGFR \<50 mL/min per 1.73 m^2^.

Study Strengths {#jah34541-sec-0024}
---------------

The strength of our study is the use of a well‐defined database with information on baseline hemoglobin, platelet count, liver function, and renal function of patients, which was not reported in most previous real‐world studies using registry database. To our knowledge, the present study is the first to directly compare the effectiveness and safety between different dosage recommendations of rivaroxaban in patients with either normal or impaired renal function.

Study Limitations {#jah34541-sec-0025}
-----------------

This study has several limitations. First, although the Taiwan AF guidelines recommend an INR range of 2 to 3 for patients treated with warfarin,[21](#jah34541-bib-0021){ref-type="ref"} the TTR was low in our cohort, and therefore, rivaroxaban following either dosage criteria would be more likely to perform better than warfarin. Indeed, a lower INR and poor TTR for Asian patients with AF receiving warfarin is a common issue. For example, the TTR for warfarin was only 44% for Taiwanese patients with AF even in the RE‐LY (Randomized Evaluation of Long‐Term Anti‐coagulation Therapy) trial.[4](#jah34541-bib-0004){ref-type="ref"} However, even compared with patients treated with warfarin in a top quartile of TTR, rivaroxaban following ROCEKT AF or J‐ROCKET AF dosage criteria was still associated with a similar risk of IS/SE and a lower risk of mortality, ICH, and all major bleeding, which were generally consistent with the principal analyses. Therefore, a low TTR in our study may not significantly confound our main findings. Second, both ROCKET AF and J‐ROCKET AF adopted the Cockcroft and Gault formula to calculate eGFR of patients to adjust the dose of rivaroxaban, while we used the Modification of Diet and Renal Disease (MDRD) equation to estimate renal function in the present study. Different from the MDRD equation, an important characteristic of the Cockcroft and Gault formula is the inclusion of total body weight in the equation, as a reflection of muscle mass, the main determinant of creatinine generation. However, we did not use the Cockcroft and Gault formula in the present study because of the lack of body weight in the electronic medical data of the Chang Gung Memorial Hospital System. In Taiwan, most biochemistry laboratories directly provide an MDRD equation--derived eGFR (mL/min per 1.73 m^2^) in keeping with the national guidance, and many physicians adopt the results from the MDRD equation instead of the Cockcroft and Gault formula to estimate the renal function of patients and determine the dose of DOACs. Previous studies indicate that MDRD equation slightly underestimates renal function at higher levels and tends to overestimate at lower levels relative to the Cockcroft and Gault formula. For the case of rivaroxaban, 0.3% would have been incorrectly judged eligible for treatment and 13.5% would have received too high a dose.[22](#jah34541-bib-0022){ref-type="ref"} However, the slight disagreement between Cockcroft and Gault and MDRD estimation may not significantly influence our analysis because we did not focus on the intragroup comparisons within the ROCKET AF (eg 20 versus 15 mg/d) or J‐ROCKET AF (eg 15 versus 10 mg/d) groups in the present study. Third, miscoding and misclassification of the underlying comorbidities and outcomes recorded by each physician\'s choice of treatment constitutes an additional limitation of the present study. Hence, our present study only used primary discharge diagnoses in order to improve the accuracies of clinical outcomes. In addition, such miscoding and misclassification are highly unlikely to be different between patients following ROCKET AF and J‐ROCKET AF dosage criteria. Fourth, although the baseline differences of comorbidities between groups have been adjusted by the multivariate regression analysis, residual unmeasured confounding and selective prescribing behavior could not be excluded in the present study. Fifth, our study was performed in an intention‐to‐treat design, and did not take the changes of dosages of rivaroxaban and eGFRs, which may result in different categorizations of patients into considerations. This important limitation should be kept in mind when interpreting the results we presented here. Sixth, we defined *P*\<0.05 as statistically significant without further adjustments for multiplicity, and, therefore, the type I error is possible to be present for some analyses. In our study, the 6 end points we defined were those also commonly tested in prior studies comparing different treatments for stroke prevention in patients with AF, which were prespecified rather than being randomly selected from many other end points. In addition to *P* values, both the point estimates and their 95% CIs were reported for each comparison, which could be helpful for readers to judge and interpret the results. Finally, the present study only enrolled Taiwanese patients; therefore, whether the results can be extrapolated to other countries in Asia remains unclear.

Conclusions {#jah34541-sec-0026}
===========

In Asian patients with NVAF taking rivaroxaban for stroke prevention, the J‐ROCKET AF dosage criteria (15/10 mg once daily) was as effective as ROCKET AF (20/15 mg once daily) and was associated with a lower risk of major bleeding in patients with impaired renal function. Compared with warfarin, rivaroxaban following either the ROCKET AF or J‐ROCKET AF dosage criteria was effective and even safer in Asian patients with AF.
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**Table S1.** *International Classification of Disease, 9th and 10th Edition, Clinical Modification* (*ICD 9‐CM* and *ICD 10‐CM*) Codes Used to Define Comorbidities and Clinical Outcome in the Study Cohort

**Table S2.** HRs and 95% CIs of 6 Outcomes for Patients With NVAF Taking Rivaroxaban Following the ROCKET AF or J‐ROCKET AF Dosage Criteria vs Patients Taking Warfarin**Table S3.** HRs and 95% CIs of 6 Outcomes for Rivaroxaban Following the ROCKET AF Dosage Criteria vs J‐ROCKET AF Dosage Criteria in Patients With NVAF With eGFR ≥50 mL/min per 1.73 m^2^ or eGFR \<50 mL/min per 1.73 m^2^

**Figure S1.** Forest plot of hazard ratios (HRs) and 95% CIs for patients with nonvalvular atrial fibrillation (NVAF) taking rivaroxaban following the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) dosage criteria or J‐ROCKET AF (Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) dosage criteria vs patients taking warfarin with the top quartile of therapeutic range (mean 61.1% for the range of international normalized ratio between 2.0 and 3.0).
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